SCHEMBL10314567

SCHEMBL10314567

Cn1c(=O)c2c(OCc3ccccc3)c(C=O)sc2c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 5/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ TP53 P04637 2/20 0.41
▸ HDAC1 Q13547 3/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ MAOB P27338 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ ACKR3 P25106 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314609 0.92 HDAC6 (0.42) HDAC6KDM4EALDH1A1HPGDNPC1
SCHEMBL12962828 0.84 HSD17B10 (0.41) KDM4EALDH1A1HPGDRAB9AMEN1
SCHEMBL10314608 0.83 KDM4E (0.41) KDM4EALDH1A1HPGDTP53TSHR
SCHEMBL10314553 0.83 TSHR (0.42) KDM4EALDH1A1RAB9AMEN1KMT2A
SCHEMBL1063175 0.82 KDM4E (0.49) HDAC6KDM4EALDH1A1HPGDNPC1
SCHEMBL1062862 0.79 HDAC6 (0.52) HDAC6KDM4EALDH1A1HPGDNPC1
SCHEMBL10314584 0.79 ALDH1A1 (0.44) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL1056831 0.78 TSHR (0.54) HDAC6KDM4EALDH1A1MEN1KMT2A
SCHEMBL10314573 0.78 KDM4E (0.46) KDM4EALDH1A1HPGDRAB9AMEN1
SCHEMBL10314348 0.77 TP53 (0.46) HDAC6KDM4EALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 HDAC6 262/4885KDM4E 528/4885ALDH1A1 745/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 HDAC6 261/4885KDM4E 464/4885ALDH1A1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback